Anti-C3 [WM1]
Invented by Prof Walter Bodmer from University of Oxford
Invented at Cancer Research UK London Research Institute: Lincoln's Inn Fields
- Datasheet
- References (2)
- Inventor Info
Info
Catalogue Number | 153253 |
Applications | IP Fn |
Antigen/Gene or Protein Targets | Human complement component 3 |
Reactivity | Human |
Relevance |
C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates. Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes. |
Host | Mouse |
Immunogen | Human complement component 3 |
Positive Control | Human primary fibroblasts |
Subclass | IgG1 lambda |
Myeloma Used | P3X63Ag8 |
Strain | Balb/c |
Notes |
The antibody will bind to C3b and C3c, but not to C3a or C3d. WM1 antibody inhibits a standard C3 hemolytic assay. The antibody was unable to immunoprecipitate rabbit or mouse C3. |
Research Area | Cell Type or Organelle Marker, Immunology, Neurobiology, Protein Degradation |
References: 2 entries
Whitehead et al. 1981. Eur J Immunol. 11(2):140-6. PMID: 6163641.
A monoclonal antibody against human complement component C3: the production of C3 by human cells in vitro.
Europe PMC ID: 6163641
Add a reference
References: 2 entries
Whitehead et al. 1981. Eur J Immunol. 11(2):140-6. PMID: 6163641.
A monoclonal antibody against human complement component C3: the production of C3 by human cells in vitro.
Add a reference